• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
GlycoMimetics, Inc. - Product Pipeline Review - Q4 2010 - Product Image

GlycoMimetics, Inc. - Product Pipeline Review - Q4 2010

  • Published: November 2010
  • Region: Global
  • 40 pages
  • Global Markets Direct

GlycoMimetics, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “GlycoMimetics, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- GlycoMimetics, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of GlycoMimetics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, READ MORE >



List of Tables
List of Figures
GlycoMimetics, Inc. Snapshot
GlycoMimetics, Inc. Overview
Key Information
Key Facts
GlycoMimetics, Inc. – Research and Development Overview
Key Therapeutic Areas
GlycoMimetics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
GlycoMimetics, Inc. – Pipeline Products Glance
GlycoMimetics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
GlycoMimetics, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
GlycoMimetics, Inc. – Drug Profiles
GMI-1070
Product Description
Mechanism of Action
R&D Progress
GMI-1051
Product Description
Mechanism of Action
R&D Progress
GMI-1070
Product Description
Mechanism of Action
R&D Progress
Anti-Infectives Program
Product Description
Mechanism of Action
R&D Progress
Anti-Inflammatory Program
Product Description
Mechanism of Action
R&D Progress
GlycoMimetics, Inc. – Pipeline Analysis
GlycoMimetics, Inc. – Pipeline Products by Therapeutic Class
GlycoMimetics, Inc. Pipeline Products By Target
GlycoMimetics, Inc. – Pipeline Products by Route of Administration
GlycoMimetics, Inc. – Pipeline Products by Molecule Type
GlycoMimetics, Inc. – Recent Pipeline Updates
GlycoMimetics, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Sep 28, 2010: GlycoMimetics Announces Publication Of Pre-Clinical Data On GMI-1070 In Sickle Cell Disease Model In Journal Blood
Jul 14, 2010: GlycoMimetics Wins Two US Patents For GMI-1070 And Related Compounds
Jun 24, 2010: GlycoMimetics Initiates Phase II Clinical Trial Of GMI-1070 In Sickle Cell Patients
Dec 07, 2009: GlycoMimetics Announces Two Oral Presentations On Lead Drug Candidate GMI-1070 At American Society Of Hematology Annual Meeting
Sep 02, 2009: GlycoMimetics Announces New Drug To Treat Sickle Cell Crisis Begins Pilot Study In Patients
Aug 16, 2009: GlycoMimetics, Inc. Awarded NIH Grant To Study Drug Candidate In Diabetes
May 28, 2009: Dana-Farber Cancer Institute Presents Results Of GlycoMimetics’ Lead Drug Candidate In Models Of Multiple Myeloma At American Society Of Clinical Oncology Annual Meeting
Mar 26, 2009: GlycoMimetics, Inc. Completes Phase 1 Clinical Studies Of Lead Drug Candidate
Sep 05, 2008: GlycoMimetics, Inc. Commences Phase 1 Clinical Trial Of Lead Drug Candidate
Dec 09, 2007: GlycoMimetics, Inc. To Present Results Of Lead Candidate In Animal Models Of Sickle Cell Disease At American Society Of Hematology Annual Meeting
Financial Deals Landscape
GlycoMimetics, Inc., Deals Summary, 2004 to 2010
GlycoMimetics, Inc. Detailed Deal Summary
Venture Financing
GlycoMimetics Raises $38 Million In Series C Financing Round
GlycoMimetics Secures $15.4 Million In Series B Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS